Rhythm Pharmaceuticals Is Well-Positioned, Analyst Says Could Capture Big Share Of Rare Obesity Market

Core Viewpoint - RBC Capital Markets initiated coverage on Rhythm Pharmaceuticals Inc., highlighting its role as a pioneer in the rare genetic obesity market, particularly following the success of its Phase 3 trial in hypothalamic obesity, which resulted in a significant stock rally and a market-cap increase of approximately $3.5 billion [1]. Group 1: Clinical and Commercial Developments - Rhythm Pharmaceuticals released topline results from the Phase 3 TRANSCEND trial in April 2025, demonstrating a statistically significant and clinically meaningful reduction in body mass index (BMI) of -19.8% compared to placebo in patients [2]. - The company markets setmelanotide under the Imcivree brand for syndromic or monogenic obesity, achieving third-quarter sales of $51.3 million [3]. - Analyst Lisa Walter indicated that Imcivree can effectively reduce BMI both as a standalone treatment and in combination with GLP-1s, addressing hunger management [3]. Group 2: Market Potential and Projections - RBC Capital Markets initiated coverage with an Outperform rating and a price target of $145, noting that 56% of surveyed physicians expect to initiate Imcivree in hypothalamic obesity patients within a year of approval [4]. - The addressable market for Imcivree is projected to expand with an estimated additional 27,000 global patients, potentially increasing revenue to exceed $2 billion by 2030 [5]. - RBC models a market penetration of up to 20% in the U.S. with peak sales projected at $1.3 billion by 2034 [7]. Group 3: Regulatory Updates - The FDA extended the review period for the supplemental New Drug Application for setmelanotide for acquired hypothalamic obesity by three months, now due on March 20, 2026 [6]. - Rhythm Pharmaceuticals is also developing setmelanotide for Prader-Willi Syndrome, indicating a broader pipeline for future growth [6].